Last week, the American Society of Addiction Medicine sent a letter to the FDA regarding the need for more medication options for people recovering from opioid addiction:

Addiction is a complex condition. Clinicians and their patients need access to multiple, nuanced treatment options to meet their unique needs and circumstances. Access to multiple formulations and dosages expands the number of available effective and safe treatment options for SUD.

Therefore, as the FDA considers applications for new products to treat SUD, ASAM hopes that the FDA takes into consideration the need for access to multiple treatment options for clinicians and their patients.

Read the full letter here.